Australian on track to eliminate Hepatitis C by 2030

Embargoed until: Publicly released: 2021-04-01 00:01

Australia; NSW

With the advent of effective ‘direct-acting antiviral’ treatments for hepatitis C, Australia is one of the 12 countries ‘on-track’ to eliminate hepatitis C by 2030, says an Australian expert. The author says prevention, screening, financial incentives and process improvement are critical strategies to reach the final goal of elimination.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Editorial / Opinion NPS MedicineWise, Web page Please link to the article in online versions of your report (the URL will go live after the embargo ends).

Journal/
conference: Australian Prescriber

Research:Paper

Organisation/s: The Kirby Institute for Infection and Immunity in Society, The University of New South Wales

Funder: Conflicts of interest: Gregory Dore is an advisory board member for and receives honoraria from Gilead, Merck and Abbvie. He has received research grant funding and travel sponsorship from Gilead, Merck and Abbvie.

Media Contact/s

Contact details are only visible to registered journalists.